In a similar fashion, miR-103 and miR-107, when overexpressed, reduced HRR and sensitized osteosarcoma cells to various DNA-damaging agents, including cisplatin and a PARP inhibitor by targeting RAD51 [118]. The gene discussed is RAD51; the disease is osteosarcoma.